Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03480568 · ClinicalTrials.gov registry record · Phase 3
Alirocumab in Patients on a Stable Dialysis Regimen
A Phase 3 study, sponsored by Baylor Research Institute.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
NCT03480568: Recruiting Phase 3 study, sponsored by Baylor Research Institute.
NCT03480568 is a Phase 3 study that is actively recruiting participants, run by Baylor Research Institute. The registered enrollment target is 20 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03480568, a Phase 3 study, is actively recruiting participants, sponsored by Baylor Research Institute.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
Study Summary
12-week study of the efficacy and safety of alirocumab in patients maintained stably on hemodialysis or peritoneal dialysis. Measures of cholesterol levels, drug levels, PCSK9 levels, routine chemistry and cell counts, and biomarkers will be obtained at baseline and at weeks 4, 8, 10 and 12 weeks. Safety events will be obtained throughout the study.
Primary Outcome
Efficacy
Interventions
- DRUG Alirocumab 150 MG/ML [Praluent]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-05-01 |
| Est. Completion | 2020-12-31 |
| Phase | Phase 3 |
What NCT03480568 shows while recruiting
NCT03480568 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Alirocumab 150 MG/ML [Praluent] is the first listed.
NCT03480568 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03480568 about?
NCT03480568 is a clinical study titled "Alirocumab in Patients on a Stable Dialysis Regimen". 12-week study of the efficacy and safety of alirocumab in patients maintained stably on hemodialysis or peritoneal dialysis. Measures of cholesterol levels, drug levels, PCSK9 levels, routine chemistry and cell counts, and biomarkers will be obtained at baseline and at weeks 4, 8, 10 and 12 weeks. S...
What is the current status of trial NCT03480568?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2018-05-01. Estimated completion is 2020-12-31.
What interventions are being tested in trial NCT03480568?
The interventions under investigation include: Alirocumab 150 MG/ML [Praluent] (DRUG).
Who is sponsoring clinical trial NCT03480568?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03480568's enrollment target sits among peer trials
20 1956th of 2000 higher than 32 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI